IL17A and chronic inflammatory demyelinating polyradiculoneuropathy: Third, prospectively quantified IL-17 production by blood T cells predicts the response to IVIg treatment in ICAM-1-/-NOD mice and intraneural IL-17 production is enhanced preferentially in early stage human CIDP patients.